Combination therapy of NHS-IL12 and avelumab enhances antitumor efficacy in preclinical cancer models. Mus musculus
收藏NIAID Data Ecosystem2026-03-10 收录
下载链接：
https://www.ncbi.nlm.nih.gov/bioproject/PRJNA360272
下载链接
链接失效反馈官方服务：
资源简介：
Nanostring gene expression profiling of 24 BALB/c mice bearing EMT-6 tumors under avelumab and NHS-muIL12 mono and combination therapies. Overall design: Six groups of four mice were profiled using samples collected on day 6. G1 is isotype control. Group 2 is 2ug NHS-muIL12. Group 3 is 10ug NHS-muIL12. Group 4 is avelumab 200ug. Group 5 is avelumab 200ug plus 2ug NHS-muIL12. Group 6 is avelumab 200ug plus 10ug NHS-muIL12.
创建时间：
2017-01-05
